Pancreatic Cancer Research

ResearcherMarche Polytechnic UniversityActive in the last 2 years

Mario Scartozzi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5977-5546; OpenAlex author ID A5034035272. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
90
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 4 papers · 2024: 1 paper · 2025: 2 papers · 2026: 4 papers

Papers 20

  1. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  2. Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study. Co-author DOI 10.1016/j.esmogo.2025.100276↗
  3. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  4. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  5. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  6. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  7. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. Co-author DOI 10.1016/j.pan.2024.09.006↗
  8. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  9. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine pl… Last author DOI 10.1016/j.dld.2022.11.012↗
  10. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  11. Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. Co-author DOI 10.3390/cancers15030900↗
  12. How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world. Co-author DOI 10.5306/wjco.v13.i5.417↗
  13. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  14. BRCA-mutant pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41416-021-01469-9↗
  15. Uncovering key targets of success for immunotherapy in pancreatic cancer. Last author DOI 10.1080/14728222.2021.2010044↗
  16. Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Last author DOI 10.1177/0300891620976945↗
  17. New therapeutic targets in pancreatic cancer. Last author DOI 10.1016/j.ctrv.2019.101926↗
  18. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2017.01.015↗
  19. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Last author DOI 10.1016/j.critrevonc.2017.03.025↗
  20. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Co-author DOI 10.18632/oncotarget.5197↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrea Pretta · 10 shared papers, 2019–2026 · strength 1.40
  2. Letizia Procaccio · 7 shared papers, 2023–2026 · strength 1.23
  3. Giulia Orsi · 7 shared papers, 2021–2026 · strength 1.07
  4. Michele Reni · 7 shared papers, 2017–2026 · strength 1.03
  5. Sara Lonardi · 6 shared papers, 2023–2026 · strength 1.00
  6. Mariacristina Di Marco · 6 shared papers, 2021–2026 · strength 1.00
  7. Marina Macchini · 6 shared papers, 2021–2026 · strength 0.98
  8. Monica Niger · 6 shared papers, 2021–2026 · strength 0.96
  9. Giampaolo Tortora · 6 shared papers, 2021–2026 · strength 0.96
  10. Michèle Milella · 6 shared papers, 2021–2026 · strength 0.93
  11. Silvia Bozzarelli · 5 shared papers, 2021–2026 · strength 0.80
  12. Ilario Giovanni Rapposelli · 5 shared papers, 2021–2026 · strength 0.80
  13. Caterina Vivaldi · 4 shared papers, 2023–2026 · strength 0.75
  14. Francesca Bergamo · 4 shared papers, 2023–2026 · strength 0.71
  15. Elisa Giommoni · 5 shared papers, 2021–2026 · strength 0.70
  16. Guido Giordano · 5 shared papers, 2021–2026 · strength 0.70
  17. Enrico Vasile · 5 shared papers, 2017–2026 · strength 0.69
  18. Eleonora Lai · 6 shared papers, 2019–2023 · strength 0.68
  19. Lisa Salvatore · 4 shared papers, 2023–2026 · strength 0.68
  20. Catia Carconi · 3 shared papers, 2024–2026 · strength 0.60
  21. Stefano Cascinu · 6 shared papers, 2015–2025 · strength 0.56
  22. Andrea Spallanzani · 4 shared papers, 2021–2025 · strength 0.55
  23. Ingrid Garajová · 4 shared papers, 2021–2025 · strength 0.55
  24. Massimo Falconi · 3 shared papers, 2017–2026 · strength 0.48
  25. Giuseppe Aprile · 4 shared papers, 2017–2026 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.